Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.48 |
| ▸ | CCR5 | P51681 | 6/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4242899 | 0.87 | GPR119 (0.51) | GPR119CCR5KCNH2 | |
| SCHEMBL4240125 | 0.86 | CCR5 (0.47) | GPR119CCR5KCNH2PGRCYP2D6 | |
| SCHEMBL4240390 | 0.86 | CCR5 (0.47) | GPR119CCR5KCNH2PGRCYP2D6 | |
| SCHEMBL4244941 | 0.86 | CCR5 (0.47) | GPR119CCR5KCNH2PGRCYP2D6 | |
| SCHEMBL4236724 | 0.84 | CCR5 (0.47) | GPR119CCR5KCNH2PGRCYP2D6 | |
| SCHEMBL4242907 | 0.83 | CCR5 (0.48) | GPR119CCR5KCNH2PGRCYP2D6 | |
| SCHEMBL312512 | 0.83 | SLC6A2 (0.50) | GPR119CCR5KCNH2PGRCYP2D6 | |
| SCHEMBL312577 | 0.82 | SLC6A2 (0.66) | GPR119CCR5PGRCYP2D6CYP2C9 | |
| SCHEMBL4116346 | 0.80 | GPR119 (0.44) | GPR119MEN1KMT2A | |
| SCHEMBL4240462 | 0.79 | GPR119 (0.54) | GPR119CCR5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491735-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1708703-A4 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC (CA) | 2008-04-09 | — | — | EP | disclosed |
| EP-1708703-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-10-11 | — | — | EP | disclosed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005059107-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277670-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | GPR119 207/4885CCR5 1/4885KCNH2 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.